A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors
Status:
Recruiting
Trial end date:
2024-05-23
Target enrollment:
Participant gender:
Summary
The purpose of this study is to characterize the safety and tolerability of IAG933 in
patients with mesothelioma, NF2/LATS1/LATS2 mutated tumors and tumors with functional YAP/TAZ
fusions and to identify the maximum tolerated dose and/or recommended dose.